BeOne Medicines Ltd. (ONC) operating KPIs
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)
Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –
BeOne Medicines bLINCYTO (blinatumomab, CD19×CD3 BiTE — Amgen In-Licensed) ($M) ($M)
Form 10-Q / 10-K Segment Disaggregation Note (XBRL)
Latest, FY2025
104
Period ended Dec 31, 2025
Change on a year earlier
+40.2%
74.3 in FY2024
History
7 years
Since FY2019
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | BLINCYTO (blinatumomab, CD19×CD3 BiTE — Amgen In-Licensed) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 104 | +40.2% | Form 10-K (filed 2026-02-26) ↗ |
| FY2024 | Dec 31, 2024 | 74.3 | +36.8% | Form 10-K (filed 2026-02-26) ↗ |
| FY2023 | Dec 31, 2023 | 54.3 | +50.4% | Form 10-K (filed 2026-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 36.1 | +188.8% | Form 10-K (filed 2025-02-27) ↗ |
| FY2021 | Dec 31, 2021 | 12.5 | – | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 0 | – | Form 10-K (filed 2023-02-27) ↗ |
| FY2019 | Dec 31, 2019 | 0 | – | Form 10-K (filed 2022-02-28) ↗ |
Cite this data
StockData. (2026). BeOne Medicines BLINCYTO (blinatumomab, CD19×CD3 BiTE — Amgen In-Licensed) ($M) ($M), annual FY2019–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod_blincyto
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.